SKYE Stock Analysis: Buy, Sell, or Hold?
SKYE - Skye Bioscience, Inc. Common Stock
$0.36
-0.06 (-13.51%)
▼
5d:
-33.63%
30d:
-45.08%
90d:
-53.84%
WAIT
LOW Confidence
Analysis Updated: Aug 18, 2026 12:00 AM ET
Earnings: Aug 20, 2026
TODAY
Get Alerted When SKYE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: SKYE is down 33.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: SKYE is down 33.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: SKYE is currently trading at $0.36, which is considered oversold relative to its 30-day fair value range of $0.50 to $0.66.
Technical Outlook: Technically, SKYE is in a downtrend. Immediate support is located at $0.28, while resistance sits at $0.88. Short-term momentum is weak, with the stock down 13.5% recently.
Market Sentiment: SKYE scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.60 (+2017.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SKYE is in a downtrend. Immediate support is located at $0.28, while resistance sits at $0.88. Short-term momentum is weak, with the stock down 13.5% recently.
Market Sentiment: SKYE scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.60 (+2017.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.50 -
$0.66
Company Quality Score
34/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-13.5%)
- BULLISH: Trading 2017.0% below Wall St target ($7.60)
- WARNING: Composite score 34/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.50 -
$0.66
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.28
Resistance Level
$0.88
Current Trend
Downtrend
Technical data as of
Aug 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.36
Wall Street Target
$7.60
(+2017.0%)
Share & Embed Analysis
Last updated: August 19, 2026 8:07 AM ET
Data refreshes hourly during market hours. Next update: 9:07 AM
Data refreshes hourly during market hours. Next update: 9:07 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SKYE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 48 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$49 | 52 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 31 SELL |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1100 | 40 SELL |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$121 | 51 HOLD |
